The Imricor Medical Systems Inc (ASX: IMR) share price is in focus today after the company announced the commercial launch of its Interventional MR (iMR) lab solution in collaboration with global imaging leader Philips. This new combined solution is immediately available in CE-marked markets and is designed to support MR-guided cardiac interventions.
What did Imricor Medical Systems report?
- Commercial launch of a combined iMR lab solution with Philips.
- The solution integrates Philips’ 1.5T BlueSeal MR platform with Imricor’s NorthStar®, Advantage-MR®, and other systems.
- Includes Imricor’s single-use catheters and interventional tools for cardiac procedures.
- Available immediately in CE-marked markets; select configurations in the US now and more pending regulatory approval.
- Scalable platform for potential expansion into new procedures and clinical areas.
What else do investors need to know?
The launch builds on Imricor’s longstanding partnership with Philips, which began in 2012 with joint technology development. The iMR lab solution is designed specifically for cardiac electrophysiology and other interventional cardiac procedures, using MR-guided imaging for improved care.
This innovative, purpose-built approach aims to move MR imaging technology directly into the procedure room, making advanced interventions safer and more effective. The collaboration positions Imricor alongside a major industry player, broadening its reach and potential customer base.
What’s next for Imricor Medical Systems?
Imricor plans to showcase the new iMR lab solution at the ESC Congress 2026 in Munich. The company expects further configurations to be launched in the United States and other geographies as regulatory clearances are achieved.
Management sees this launch as a foundation for future growth, with ambitions to expand the platform into new clinical areas beyond cardiac electrophysiology. The partnership with Philips could pave the way for increased adoption of MR-guided interventions globally.
Imricor Medical Systems share price snapshot
Over the past 12 months, Imricor shares have risen 39%, outperforming the All Ordinaries Index (ASX: XAO).
The post Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab appeared first on The Motley Fool Australia.
Should you invest $1,000 in Imricor Medical Systems right now?
Before you buy Imricor Medical Systems shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imricor Medical Systems wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- 2 ASX healthcare stocks tipped to return 34% to 63%
- Imricor Medical Systems shares: Philips declares compatibility for iMR products
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.